Filing Flows › Biotricity (BTCY) › Q1 FY27 › vs Q1 FY26
Biotricity (BTCY) Q1 FY27 vs Q1 FY26 (year over year)
Biotricity's revenue rose $403K (+10%) from $3.9M in Q1 FY26 to $4.3M in Q1 FY27. The biggest changes: Technology Fees +$795K (+24%); Device Sales −$392K (-78%).
Biotricity, Q1 FY27: revenue $4.3M (+10% year over year), operating margin 3.7%, net loss $959K, operating cash flow $507K. The chart draws each line against Q1 FY26, the increases inside each band.
Every line
| Line | Q1 FY27 | Q1 FY26 | Change | % |
|---|---|---|---|---|
| Technology Fees | $4.2M | $3.4M | $795K | +24% |
| Device Sales | $111K | $503K | −$392K | -78% |
| Revenue | $4.3M | $3.9M | $403K | +10% |
| Net loss | $959K | $672K | $287K | +43% |
| Costs & expenses | $5.2M | $4.5M | $690K | +15% |
| Operating costs | $4.1M | $3.6M | $527K | +15% |
| Interest & other, net | $1.1M | $954K | $164K | +17% |
| Cost of revenue | $746K | $757K | −$11K | -1% |
| Research & development | $673K | $696K | −$23K | -3% |
| SG&A | $2.7M | $2.1M | $561K | +26% |
| Operating cash sources | $1.5M | $299K | $1.2M | +391% |
| Depreciation | $1K | $1K | $0 | 0% |
| Share-based compensation | $340K | $6K | $334K | 57× |
| Working capital & other | $1.1M | $291K | $834K | +286% |
| Net loss absorbed | $959K | $672K | $287K | +43% |
| Operating cash flow | $507K | −$373K | $881K | — |
Questions
How much did Biotricity's revenue grow year over year in Q1 FY27?
Biotricity's revenue rose $403K (+10%) from $3.9M in Q1 FY26 to $4.3M in Q1 FY27.
What drove Biotricity's revenue change in Q1 FY27?
Technology Fees +$795K (+24%); Device Sales −$392K (-78%).